

# Feasibility and Efficacy of Highly Active Antiretroviral Therapy Among High-Risk HIV-1 Infected Women in West Africa

Charlotte Huet<sup>1</sup>, Abdoulaye Ouedraogo<sup>1</sup>, Issouf Konaté<sup>1</sup>, Jean-Louis Ouedraogo<sup>1</sup>, <u>Isidore Traoré<sup>1</sup></u>, François Rouet<sup>1</sup>, Adama Ouiminga<sup>1</sup>, Anselme Sanon<sup>1</sup>, Ramata Diallo<sup>1</sup>, Philippe Mayaud<sup>2</sup>, Nicolas Nagot<sup>1-3</sup>, Philippe Van De Perre<sup>3</sup>, for the ANRS 1222 Yerelon Study Group


<sup>1</sup>Centre Muraz, Bobo-Dioulasso, Burkina Faso; <sup>2</sup>London School of Hygiene & Tropical Medicine, London, United Kingdom; <sup>3</sup>Université Montpellier 1, EA 4205 «Transmission, Pathogenèse et Prévention de l'Infection par le VIH », Montpellier, France

### **OBJECTIVES**

To describe the long-term clinical, immunological and virological outcomes of HAART among HIV-infected female sex workers (FSWs) in Burkina Faso

## **METHODS**

- Design: prospective observational open cohort study nested within the Yerelon cohort of high-risk women living in Bobo-Dioulasso, Burkina Faso
- HIV-1 infected women initiated on HAART according to WHO recommendations
- Follow-up included:
- monthly clinical visits
- specific drug adherence support provided by psychologists and peer-educators







- HAART adherence assessment
- 6-monthly CD4+ cell count and plasma HIV-1 RNA measurements (RT-PCR)
- Cotrimoxazole prophylaxis, HAART and medical care provided free of charge

# **RESULTS**

### **BASELINE**

- 95 HIV-1 women enrolled including 47 FSWs
- WHO clinical stages III/IV: FSWs: 70%, non-FSWs: 69%
- Median CD4+ count:
  - FSWs: 147 cells/µl (IQR, 79-183) non-FSWs: 144 cells/µl (IQR, 100-197)
- Mean HIV-1 plasma viral load: FSWs: 4.94 log<sub>10</sub>copies/mL (95%CI, 4.70-5.18) non-FSWs: 5.15 log<sub>10</sub>copies/mL (95%CI, 4.97-5.33)
- HAART regimen (for 97% of women):
  2 INRT [AZT or d4T + 3TC] + 1 INNRT [efavirenz or nevirapine]

#### FOLLOW-UP

- Median follow-up: 32 months (IQR, 20-41)
- 4 deaths (all FSWs), mortality rate: 1.7 per 100 pers-year
- 7 women lost to follow-up (2 FSWs)

Months of treatment

- Survival probability among FSWs: 0.91 (95%CI, 0.78-0.97) at M36 after HAART initiation
- High adherence to HAART (>95% pills taken) among FSWs:
  - 83.3% (95% CI, 67.2-93.6) at M6; 100% (95% CI, 54.1-100.0) at M36
  - No difference compared with non-FSWs
- Drug-related adverse events (required regimen modification):
  - -AZT: 4 severe anaemia (grades 3 or 4, ANRS scaling system)
  - -ddl/d4T: 1 peripheral neuropathy
  - -efavirenz: 1 central neurological disturbance
- **CONCLUSIONS**
- •Marginalised groups such as FSWs can sustain high drug adherence level in Africa
- Benefits similar to other groups can be sustained over the long term
- National programmes should not neglect improving access to HAART for this high-risk and marginalised population

- Rate of CD4 cell count gain at M36 (Top panel, Figure) FSWs: 230 cells/µl (IQR, 90-400) non-FSWs: 284 cells/µl (IQR, 193-420)
- Percentage of patients with undetectable HIV-1 viral load (Bottom panel, Figure) FSWs: 81.8% (95%CI, 59.7-94.8) non-FSWs: 100% (95%CI, 83.9-100.0)



With support from:





Programme for Research & Capacity Building on Sexual & Reproductive Health & HIV in Developing Countries